Dr. Frédérique Vegran - immuno oncology - Best Researcher Award

INSERM - France

Author Profile

🎓 Early academic pursuits

Frédérique Vegran began her scientific journey with a strong foundation in cellular and molecular biology, earning her phd in this domain. during her early academic years, she exhibited a keen interest in understanding cellular behavior under varying physiological conditions. this led her to pursue advanced studies and training in belgium, where she spent three years as a post-doctoral researcher. her research during this time revolved around the tumor microenvironment, hypoxia, and metabolic regulation—areas that laid the groundwork for her future focus in immuno-oncology, a field now evolving alongside advancements in power electronics and biotechnology integration.

🧪 Professional endeavors

Currently a full-time research scientist at inserm umr1231 in dijon, france, frédérique vegran has established herself as a leading figure in immuno-oncology. her professional tenure is marked by active involvement in cutting-edge research aimed at enhancing anti-tumor immune responses. she has supervised multiple phd candidates and participated in thesis evaluation committees, highlighting her commitment to nurturing future generations of scientists. her involvement in research also bridges academic curiosity with translational potential—something akin to the precision and adaptability found in modern power electronics systems.

🔬 Contributions and research focus

Vegran’s groundbreaking contributions have significantly advanced our understanding of t cell biology in cancer. one of her landmark findings includes the role of il-1b in promoting the anti-tumor effect of th9 cells (nature immunology, 2013). she also revealed a novel transcriptional function of nlrp3 in th2 cells (nature immunology, 2015), and more recently, identified the immuno oncology regulatory role of nlrp3 in th17 differentiation and its acquisition of treg-like properties within tumor environments (cellular and molecular immunology, 2025). such insights have reinforced the importance of targeted immune modulation—an idea resonating with the fine-tuning concepts used in power electronics.

🌍 Impact and influence

Her influence extends beyond publications, with an h-index of 37 and i10 index of 52, demonstrating consistent citation and global recognition of her work. having authored over 67 peer- immuno oncology reviewed articles, including in top-tier journals, frédérique vegran continues to impact the scientific discourse in immuno-oncology. her discoveries have paved new avenues for therapeutic strategies, inspiring researchers globally to explore the interplay between immune cells and cancer. her professional memberships with the french society of immunology (sfi) and the french society for immunotherapy of cancer (fitc) further signify her standing in the field.

📊 Academic cites

Vegran’s academic output is notable with 67 journal publications indexed in scopus and sci, alongside 8 completed and 3 ongoing research projects. she has contributed to 3 immuno oncology consultancy/industry-related projects and has 2 patents published, highlighting her dual focus on innovation and application. although she has not authored books, her work stands as a valuable reference across the immunological and oncological academic landscapes.

🧬 Legacy and future contributions

Frédérique Vegran’s legacy lies in the transformative nature of her research on immune modulation in cancer. her consistent engagement in phd mentorship, cutting-edge experimentation, and scientific evaluation sets a strong example for academic leadership. looking ahead, her research is poised to further decode immune-cancer interactions, potentially contributing to the development of novel therapeutic interventions that integrate cellular biology with advanced technologies, much like how power electronics revolutionized modern engineering systems.

Notable Publications

Title: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Authors: P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, ...
Journal: The Journal of Clinical Investigation
Title: Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis
Authors: F. Végran, R. Boidot, C. Michiels, P. Sonveaux, O. Feron
Journal: Cancer Research
Title: Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
Authors: M. Bruchard, G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, ...
Journal: Nature Medicine
Title: Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis
Authors: P. Sonveaux, T. Copetti, C.J. De Saedeleer, F. Vegran, J. Verrax, ...
Journal: PLOS ONE
Title: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation
Authors: M. Bruchard, C. Rebé, V. Derangère, D. Togbé, B. Ryffel, R. Boidot, ...
Journal: Nature Immunolog

🎓 Early academic pursuits

Melania Tesio embarked on her academic journey with a solid foundation in medical biotechnology, earning her degree with full honors from the university of torino, italy, in 2002. her passion for oncology led her to pursue a doctoral degree, culminating in a ph.d. in human oncology in 2007. her studies were uniquely enriched by a dual affiliation with the university of torino and the weizmann institute of science, israel, where she collaborated on groundbreaking research projects that laid the groundwork for her future contributions to cancer research.

🧪 Professional endeavors

Following her ph.d., Melania transitioned into impactful research roles. from 2007 to 2008, she worked as a postdoctoral researcher at the weizmann institute of science under prof. tsvee lapidot, where she delved into hematopoietic and immune system dynamics. subsequently, she joined the german cancer research center (dkfz) in 2008, collaborating with prof. andreas trumpp until 2014. since 2017, she has been a researcher at inserm, contributing significantly to unit u1111, lyon, france, where she focuses on translational cancer research while balancing her roles during maternity leave and part-time work.

🔬 Contributions and research focus

Melania's research has consistently centered on understanding the molecular mechanisms underpinning cancer, particularly t-cell acute lymphoblastic leukemia (t-all). her studies have uncovered critical insights into metabolic rewiring induced by genetic abnormalities, such as pten loss. she has also contributed to elucidating Oncologia the molecular blueprints of thymopoiesis and enhancer activation in tcr development. her recent work as a senior researcher has focused on the intersection of metabolism and oncogenesis, driving innovative therapeutic strategies for blood cancers.

🏆 Accolades and recognition

Melania’s contributions have been widely recognized in the scientific community. with an h-index of 19 and over 2,800 citations, her work has significantly impacted Oncologia cancer biology. she has been the last and corresponding author on prestigious publications, showcasing her leadership in collaborative research. her groundbreaking findings have been published in high-impact journals like blood advances, leukemia, and j experimental medicine, further establishing her as a thought leader in oncology research.

🌟 Impact and influence

Through her pioneering research, melania has advanced the understanding of key biological pathways in leukemia, offering new avenues for therapeutic Oncologia interventions. her work on age-related clinical features of pten abnormalities in t-all and molecular mechanisms of tcr enhancer activation has provided valuable frameworks for clinical applications. as a mentor, she has inspired the next generation of researchers, fostering a culture of innovation and collaboration.

🌍 Legacy and future contributions

Melania’s legacy is deeply rooted in her commitment to translational oncology, where she bridges the gap between fundamental research and clinical applications. looking ahead, she aims to expand her research into metabolic dependencies in cancer, paving the way for precision medicine approaches. her dedication to unraveling complex biological systems continues to shape the field of cancer research, ensuring lasting contributions to scientific progress and patient care.

Notable Publications

Title: Tell me who you go with and I'll tell you who you are
Author: M. Tesio
Journal: HemaSphere, 2024, 8(1), e36

Title: Editorial: Tyrosine kinases and phosphatases in T-cell malignancies
Author: M. Tesio
Journal: Frontiers in Oncology, 2024, 14, 1372133

Title: Sunscreen to Protect the Marrow
Author: M. Tesio
Journal: HemaSphere, 2023, 7(9), pp. E941

Title: Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
Author: M. Tesio
Journal: HemaSphere, 2023, 7(2), pp. E827

Title: Reporting From the First EHA Research Conference: Exciting Science With Panoramic Views
Author: M. Tesio
Journal: HemaSphere, 2023, 7(1), pp. E816